Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Journal
The Lancet Oncology
Journal Volume
10
Journal Issue
1
Pages
25-34
Date Issued
2009
Author(s)
Kang Y.-K.
Chen Z.
Tsao C.-J.
Qin S.
Kim J.S.
Luo R.
Feng J.
Ye S.
Yang T.-S.
Xu J.
Sun Y.
Liang H.
Liu J.
Wang J.
Tak W.Y.
Pan H.
Burock K.
Zou J.
Voliotis D.
Guan Z.
SDGs
Other Subjects
placebo; sorafenib; adult; advanced cancer; aged; alopecia; anorexia; article; ascites; Asia; China; clinical trial; controlled clinical trial; controlled study; desquamation; diarrhea; disease control; disease course; double blind procedure; drug dose reduction; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; female; hand foot syndrome; human; hypertension; interactive voice response system; liver cell carcinoma; liver dysfunction; liver function; major clinical study; male; medical decision making; multicenter study; multiple cycle treatment; nausea; outcome assessment; overall survival; phase 3 clinical trial; priority journal; randomized controlled trial; rash; South Korea; Taiwan; treatment outcome; upper gastrointestinal bleeding; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyridines
Type
journal article